Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
42 participants
INTERVENTIONAL
2025-07-09
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Parkinson's disease (PD) affects over 10 million people globally. Despite optimal pharmacological treatment, approximately 70% of individuals experience unstable gait and falls, leading to loss of confidence, social isolation, fractures, and frequent hospitalisations. Treadmill training-especially when augmented by mechanical or virtual-reality perturbations-has shown promise in improving gait and reducing fall risk. However, the mechanisms underlying these benefits remain poorly understood, limiting the ability to personalise interventions effectively.
This randomised controlled trial (RCT) forms part of the broader Steps Against the Burden of Parkinson's Disease project (CT-IDs: 6ef2e427b002, 6ef2e427b003, 6ef2e427b004), comprising three harmonised but independently conducted RCTs. All sites follow a shared core protocol, allowing for pooled data analysis while preserving site-specific perturbation adaptations. Findings from this trial will be reported both independently and as part of the combined dataset.
In this trial, participants with PD will undergo 12 sessions of treadmill training, with or without virtual reality and perturbation-based adaptations. Assessments will be conducted at baseline, post-training, and follow-up. The intervention aims to enhance gait through improved sensorimotor integration and balance control. During the follow-up period, a smartphoneapp "Walking Tall" will be used to encourage continued exercises and long-term retention of training effects.
Biomechanical analyses will focus on changes in foot placement control. Neurophysiological outcomes will be examined using EEG and EMG, targeting reductions in beta-band EEG power and enhanced EEG-EMG coherence as markers of improved gait stability.
Recognising that laboratory-based improvements may not always translate to daily life, this study will also investigate gait self-efficacy as a potential moderator of transfer. Remote monitoring tools will capture real-world mobility outcomes over a week. Machine learning techniques will be employed to identify factors differentiating those who improve in both settings from those who do not. These insights will inform the development of personalised interventions capable of translating training effects into meaningful real-life outcomes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Steps Against the Burden of Parkinson's Disease - StepuP
NCT06538909
Steps Against the Burden of Parkinson's Disease - TelAviv/Bologna
NCT07105787
Steps Against the Burden of Parkinson's Disease - RCT Kiel
NCT07058285
The WalkingTall Study: Comparing WalkingTall With Parkinson's Disease (WalkingTall-PD) With Mobility-plus to Reduce Falls and Improve Mobility.
NCT04613141
A Novel Technology-assisted Home Based Aerobic Exercise Programme for Individuals With Parkinson's Disease
NCT05737316
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ii. Objectives
The objectives of the StepuP project are to:
1. Understand the kinematic and neural mechanisms that underlie improvements in gait due to treadmill training with and without mechanically and VR-triggered gait adaptations in people with PD.
2. Assess the extent to which gait improvements measured in the laboratory transfer to improvements in daily-life mobility.
3. Identify the mechanisms that support or limit the transfer of training effects from lab-based gait improvements to real-world mobility.
4. Determine for whom treadmill training improves gait characteristics in the lab and for whom it does not, and similarly, who benefits in terms of daily-life mobility.
Achieving these objectives will advance understanding of the variability in individual response to treadmill training, allowing more targeted and ultimately personalised interventions to improve outcomes in PD.
iii. Endpoints This trial will evaluate the effects of treadmill training with and without perturbations on gait performance and neural correlates in people with PD.
Primary endpoint:
\> Change in gait speed under controlled treadmill conditions.
Secondary endpoints:
* Clinical outcomes: Changes in motor symptoms and function measured through clinical assessments.
* Kinematic outcomes: Changes in gait parameters such as step length and variability from baseline to follow-up.
* Neurophysiological outcomes: EEG and EMG markers, including changes in EEG beta power and EEG-EMG coherence.
Exploratory endpoints:
* Real-world gait metrics assessed via wearable sensors.
* Gait self-efficacy assessed with validated questionnaires to examine psychological influences on transfer.
These outcomes will help identify how and for whom treadmill training leads to meaningful, lasting improvements in mobility.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Speed-dependent treadmill training (SDTT)
SDTT adjusts the treadmill's speed in real time to match an individual's walking pace, creating a dynamic and adaptive training environment. This approach simulates real-world walking conditions, promoting neuromuscular coordination, balance, and functional mobility. By tailoring speed to the user's natural gait, SDTT supports the development of efficient and more natural walking patterns. It has shown promise across clinical populations, including those with neurological disorders, musculoskeletal conditions, or recovering from injury. Its flexibility allows for progressive challenge as walking ability improves, making SDTT a valuable tool for optimising gait and mobility outcomes.
Exercise
SDTT adjusts the treadmill's speed in real time to match an individual's walking pace, creating a dynamic and adaptive training environment. This approach simulates real-world walking conditions, promoting neuromuscular coordination, balance, and functional mobility. By tailoring speed to the user's natural gait, SDTT supports the development of efficient and more natural walking patterns. It has shown promise across clinical populations, including those with neurological disorders, musculoskeletal conditions, or recovering from injury. Its flexibility allows for progressive challenge as walking ability improves, making SDTT a valuable tool for optimising gait and mobility outcomes.
SDTT+ perturbations + VR triggered adaptations
The SDTT+ program combines speed-dependent treadmill training with perturbations and VR-triggered adaptations. Reactive gait responses are elicited through controlled accelerations and decelerations of treadmill belts, simulating real-life balance challenges.
Exercise
The SDTT+ program combines speed-dependent treadmill training with perturbations and VR-triggered adaptations. Reactive gait responses are elicited through controlled accelerations and decelerations of treadmill belts, simulating real-life balance challenges.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise
SDTT adjusts the treadmill's speed in real time to match an individual's walking pace, creating a dynamic and adaptive training environment. This approach simulates real-world walking conditions, promoting neuromuscular coordination, balance, and functional mobility. By tailoring speed to the user's natural gait, SDTT supports the development of efficient and more natural walking patterns. It has shown promise across clinical populations, including those with neurological disorders, musculoskeletal conditions, or recovering from injury. Its flexibility allows for progressive challenge as walking ability improves, making SDTT a valuable tool for optimising gait and mobility outcomes.
Exercise
The SDTT+ program combines speed-dependent treadmill training with perturbations and VR-triggered adaptations. Reactive gait responses are elicited through controlled accelerations and decelerations of treadmill belts, simulating real-life balance challenges.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Hoehn and Yahr stages I to III;
3. Movement Disorder Society-sponsored version of the Unified Parkinson Disease Rating Scale (MDS-UPDRS) gait sub-score of 1 or more
4. Signed informed consent to participation
Exclusion Criteria
* Moderate or severe depression (BDI-II ≥18)
* Cognitive impairment which may preclude the possibility to provide a fully informed consent to enrolment.
* Linguistic comprehension capacity less than 75% in ordinary conversation
* Severe psychiatric comorbidity which may interfere with compliance to the study protocol
* History of or current status of substance dependency
* Unable to walk less than 1 floor
* Thoracic pain in the last 4 weeks
* Currently enrolled in other interventional studies
* Implanted Deep Brain Stimulation device
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neuroscience Research Australia
OTHER
VU University of Amsterdam
OTHER
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
Shake it up Australia Foundation
UNKNOWN
Tel Aviv Medical Center
OTHER
The University of New South Wales
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yoshiro Okubo
Conjoint Senior Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew Brodie, PhD
Role: STUDY_CHAIR
University of New South Wales
Yoshiro Okubo, PhD
Role: PRINCIPAL_INVESTIGATOR
Neuroscience Research Australia, University of New South Wales
Daniel Chan, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
University of New South Wales
Luca Modenese, PhD
Role: PRINCIPAL_INVESTIGATOR
University of New South Wales
Frederic von Wegner, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
University of New South Wales
Phu Hoang, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
Neuroscience Research Australia
Husna Razee, PhD
Role: PRINCIPAL_INVESTIGATOR
University of New South Wales
Paulo Silva Pelicioni, PhD
Role: PRINCIPAL_INVESTIGATOR
University of New South Wales
Vicki Miller
Role: PRINCIPAL_INVESTIGATOR
Shake it up Australia Foundation
Carolyn Sue, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
Neuroscience Research Australia
Martin Ostrowski, PhD
Role: PRINCIPAL_INVESTIGATOR
University of New South Wales
Mayna Ratanapongleka
Role: PRINCIPAL_INVESTIGATOR
Neuroscience Research Australia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neuroscience Research Australia
Randwick, New South Wales, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022885
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
iRECS5114
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.